Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.

Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.

Item
http://www.wikidata.org/entity/Q37417886
Interconversion of the Specificities of Human Lysosomal Enzymes Associated with Fabry and Schindler DiseasesHuman Alpha Galactosidases Transiently Produced in Nicotiana benthamiana Leaves: New Insights in Substrate Specificities with Relevance for Fabry DiseaseMucosal and peripheral Lin- HLA-DR+ CD11c/123- CD13+ CD14- mononuclear cells are preferentially infected during acute simian immunodeficiency virus infection.Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneysDistributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.Activities of genes controlling sphingolipid metabolism in human fibroblasts treated with flavonoids.Protease-resistant modified human β-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis modelFabry disease: experience of screening dialysis patients for Fabry disease.Treatment of lysosomal storage disorders: successes and challenges.Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.Biochemical and structural study on a S529V mutant acid α-glucosidase responsive to pharmacological chaperones.Fabry disease
P2860

Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.

Item
http://www.wikidata.org/entity/Q37417886
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of a modified alpha-N-acet ...... ent therapy for Fabry disease.
@en
Use of a modified alpha-N-acet ...... ent therapy for Fabry disease.
@nl
type
label
Use of a modified alpha-N-acet ...... ent therapy for Fabry disease.
@en
Use of a modified alpha-N-acet ...... ent therapy for Fabry disease.
@nl
prefLabel
Use of a modified alpha-N-acet ...... ent therapy for Fabry disease.
@en
Use of a modified alpha-N-acet ...... ent therapy for Fabry disease.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Use of a modified alpha-N-acet ...... ent therapy for Fabry disease.
@en
P2093
P2860
P304
P31
P356
10.1016/J.AJHG.2009.09.016
P407
P433
P478
P577
P5875
P698
P921
P932